DHEA: why, when, and how much--DHEA replacement in adrenal insufficiency

Area of Science:

• Endocrinology
• Metabolic Disorders
• Pharmacology

Background:

• Current glucocorticoid and mineralocorticoid replacement therapy for adrenal insufficiency (AI) inadequately restores health-related quality of life.
• The zona reticularis's function, often impaired in AI, produces androgens like DHEA, suggesting a potential therapeutic target.

Purpose of the Study:

• To evaluate the potential benefits of dehydroepiandrosterone (DHEA) replacement therapy in patients with adrenal insufficiency (AI).
• To assess DHEA's impact on quality of life, well-being, and hormonal profiles in AI patients.

Main Methods:

• Review of available studies investigating DHEA supplementation in AI patients.
• Analysis of reported effects on health perception, vitality, fatigue, sexuality, androgen levels, and IGF-1.

Main Results:

• Available studies suggest DHEA may improve health perception, vitality, and reduce fatigue in AI patients.
• DHEA effectively restores low circulating androgens in women to normal ranges and increases IGF-1 levels.
• Reported side effects are generally mild and related to DHEA's androgenic activity in women, including acne and hair changes.

Conclusions:

• DHEA shows promise for improving well-being in AI patients, particularly women, but not all studies show significant effects, possibly due to sample size and duration.
• Larger, longer-term trials (12-24 months) are necessary to definitively establish DHEA's role in AI treatment.
• While not yet standard care, compassionate use of DHEA may be considered for individual AI patients with persistent impaired well-being.